Department of Bioengineering and Therapeutic Sciences

Drug delivery research led by UCSF’s Tejal Desai, PhD, will now be supported by an exclusive worldwide license agreement between UCSF and Zcube

US$1 billion budget gap, student fee increases likely to continue, Levens Lipton keynote address to CPhA, Nkansah and the Dr. Oz television show, Bero and The Cochrane Collaboration and the World Health Assembly, Roy unveils model of bioartificial kidney; Faculty awards: Huang, Galonić Fujimori,...

The bacteria in the human gut that produce antibiotics are the focus of a US$1 million W. M. Keck Foundation grant being led by Michael Fischbach, PhD, a faculty member in the UCSF School of Pharmacy.

Table of contents


Introduction
Budget significance
Reasons for past success
A decade of funding for bioinformatics
New drug discovery directions attract support

The implantable bioartificial kidney is explained in this December 6, 2010, SmartPlanet video featuring Shuvo Roy, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine.

Shuvo Roy, PhD, an engineer and research scientist, is leading a U.S. project to build the world’s first bioartificial kidney to treat end stage renal disease. The goal is to surgically implant this coffee-cup-sized device in a human patient within 5 to 7 years.

Paul Ortiz de Montellano, PhD, is the newly appointed associate dean of research in the UCSF School of Pharmacy.

Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine, will receive the 2010 Therapeutic Frontiers Lecture Award from the American College of Clinical Pharmacy on October 17, 2010, in Austin, Texas at

UCSF, Harvard University, and Stanford University have been ranked as the top three world universities in the broad subject fields of clinical medicine and pharmacy in the 2010 Academic Ranking of World Universities (ARWU), which was released on August 15, 2010, by the Center

A national research project is under way to develop an surgically implantable bioartificial kidney using the latest advances in science and technology with the goal of both improving the health and lives of patients with end stage renal disease and saving health care dollars.